<DOC>
	<DOCNO>NCT00610012</DOCNO>
	<brief_summary>The purpose registry record information therapy reality metastatic locally advanced Renal Cell Carcinoma office-based medical oncologist Germany .</brief_summary>
	<brief_title>Tumor Registry Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description>The RCC Registry prospective , longitudinal , nation wide cohort study collect data treatment reality patient mRCC . At inclusion , data patient characteristic , comorbidities , tumor characteristic , previous treatment collect . During course observation data systemic treatment , radiotherapy , surgery , outcome document . Patients follow death maximum 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Patients metastatic locally advanced Renal Cell Carcinoma require therapy Start first palliative therapy within 1 year enrollment patient registry ; since enrollment 1000 Patients : start first palliative therapy within 4 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced Renal Cell Carcinoma</keyword>
	<keyword>MRCC</keyword>
	<keyword>Therapy-reality</keyword>
	<keyword>Observation</keyword>
	<keyword>Registry</keyword>
	<keyword>RCC</keyword>
	<keyword>ARCC</keyword>
	<keyword>Germany</keyword>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Renal Cell Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Interferon</keyword>
	<keyword>Interleukin</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>Cytokines</keyword>
	<keyword>VEGF</keyword>
</DOC>